Browsing by Author Shepherd, Gillian

Jump to: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
or enter first few letters:  
Showing results 1 to 5 of 5
Issue DateTitleAuthor(s)Citation
2009Blood pressure changes associated with sibutramine and weight management - an analysis from the 6-week lead-in period of the sibutramine cardiovascular outcomes trial (SCOUT)Caterson, Ian; Bacher, H; Coutinho, Walmir; Finer, Nick; James, W; Maggioni, Aldo; Sharma, Arya; Shepherd, Gillian; Torp-Pedersen, Christian; Van Gaal, L; Boden InstituteBlood pressure changes associated with sibutramine and weight management - an analysis from the 6-week lead-in period of the sibutramine cardiovascular outcomes trial (SCOUT), Diabetes, Obesity and Metabolism, vol.11, N/A, 2009,pp 239-250
2010Early Response to Sibutramine in Patients Not Meeting Current Label Criteria: Preliminary Analysis of SCOUT Lead-in PeriodCaterson, Ian; Coutinho, Walmir; Finer, Nick; Ge, Hong; James, Philip; Maggioni, Aldo; Santoro, Donatella; Sharma, Arya; Shepherd, Gillian; Torp-Pedersen, Christian; Van Gaal, Luc; Boden InstituteEarly Response to Sibutramine in Patients Not Meeting Current Label Criteria: Preliminary Analysis of SCOUT Lead-in Period, Obesity, vol.18, 5, 2010,pp 987-994
2010Effect of Sibutramine on Cardiovascular Outcomes in Overweight and Obese SubjectsCaterson, Ian; Coutinho, Walmir; Finer, Nick; James, W; Maggioni, Aldo Pietro; Renz, Cheryl; Rode, Richard; Sharma, Arya; Shepherd, Gillian; Torp-Pedersen, Christian; Van Gaal, Luc; School of Molecular BioscienceEffect of Sibutramine on Cardiovascular Outcomes in Overweight and Obese Subjects, New England Journal of Medicine, vol.363, 10,pp 905-917
2012Maintained Intentional Weight Loss Reduces Cardiovascular Outcomes: Results from the Sibutramine Cardiovascular OUTcomes (SCOUT) TrialCaterson, Ian; Coutinho, Walmir; et al, various; Finer, Nick; Legler, U; Maggioni, Aldo; Rode, Richard; Sharma, Arya; Shepherd, Gillian; Torp-Pedersen, Christian; Van Gaal, Luc; Molecular BioscienceMaintained Intentional Weight Loss Reduces Cardiovascular Outcomes: Results from the Sibutramine Cardiovascular OUTcomes (SCOUT) Trial, Diabetes, Obesity and Metabolism, vol.14, 6, 2012,pp 523-530
2008Tolerability of Sibutramine During a 6-week Treatment Period in High-Risk Patients With Cardiovascular Disease and/or Diabetes: A Preliminary Analysis of the Sibutramine Cardiovascular Outcomes (SCOUT) TrialCaterson, Ian; Bacher, Peter; Coutinho, Walmir; Finer, Nick; James, Philip; Maggioni, Aldo; Sharma, Arya; Shepherd, Gillian; Sun, Rui; Torp-Pedersen, Christian; Van Gaal, Luc; Boden InstituteTolerability of Sibutramine During a 6-week Treatment Period in High-Risk Patients With Cardiovascular Disease and/or Diabetes: A Preliminary Analysis of the Sibutramine Cardiovascular Outcomes (SCOUT) Trial, Journal of Cardiovascular Pharmacology, vol.52, 5, 2008,pp 393-402